Detalles de la búsqueda
1.
Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Expert Opin Pharmacother
; 24(10): 1205-1214, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37219406
2.
Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Expert Opin Pharmacother
; 22(1): 121-129, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-32892660
3.
Experience of patisiran with transthyretin stabilizers in patients with hereditary transthyretin-mediated amyloidosis.
Neurodegener Dis Manag
; 10(5): 289-300, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32519928
4.
An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Expert Opin Pharmacother
; 20(4): 473-481, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-30489166
5.
Evaluating Prognostic Factors for Liver Transplantation Among United States Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis Using National Registry Data.
Prog Transplant
; 29(3): 213-219, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31167608
6.
Intermediate Services After Behavioral Health Hospitalization: Effect on Rehospitalization and Emergency Department Visits.
Psychiatr Serv
; 67(11): 1175-1182, 2016 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27301762
7.
Patient factors contributing to variation in same-hospital readmission rate.
Med Care Res Rev
; 72(3): 338-58, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25824244
8.
Response to the letter to the editor on "an indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy".
Expert Opin Pharmacother
; 20(12): 1529-1530, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31124741
Resultados
1 -
8
de 8
1
Próxima >
>>